PATENT CLAIM ANALYSIS

Application Number: 16028112
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "101000"]

Abstract:
The present invention includes composition and methods for inhibiting or decreasing impaired systolic ejection fraction associated with cardiotoxic therapeutic treatment in a subject receiving a cardiotoxic chemotherapeutic agent causing impaired systolic ejection fraction comprising: identifying a subject in need of cardioprotection from the therapeutic treatment; and delivering an effective amount of a phospholipid or derivatives thereof that is cardioprotective to the heart of the subject thereby inhibiting or decreasing impaired systolic ejection fraction associated with administration of the cardiotoxic chemotherapeutic treatment to the subject.

Claim (Index 19):
The composition of  claim 18 , wherein the cardiotoxic therapeutic treatment is chemotherapy, wherein the one or more phospholipids is provided at least one of: before, during, or after the cardiotoxic therapeutic treatment, or wherein the one or more phospholipids is a phosphatidylglycerol that is delivered in combination with an active agent that also treats the cardiovascular disease.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 95.0
- Lexical Diversity: 1.70588
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15297901', '15347381', '15788683', '14729940', '14844475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7697693680913764
- 35 USC 102 Novelty (BERT): 0.5136442874519778
- Combined Prediction Score: 0.7441568600274365
- Mean Citation Score: 261.440028
- Max Citation Score: 279.11548
- Similarity Product: 189.65194349849705

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test